SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)

144 - Neumora Therapeutics, Inc. (0001885522) (Subject)

S-8 - Neumora Therapeutics, Inc. (0001885522) (Filer)

POS AM - Neumora Therapeutics, Inc. (0001885522) (Filer)

10-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

POSASR - Neumora Therapeutics, Inc. (0001885522) (Filer)

8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

8-K/A - Neumora Therapeutics, Inc. (0001885522) (Filer)

144 - Neumora Therapeutics, Inc. (0001885522) (Subject)

144 - Neumora Therapeutics, Inc. (0001885522) (Subject)

144 - Neumora Therapeutics, Inc. (0001885522) (Subject)

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About NeumoraNeumora Therapeutics, Inc.

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer's disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position with $307.6 million in cash, cash equivalents and marketable securities expected to support operations into mid-2026 WATERTOWN, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline c

Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced th

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans to further analyze results Navacaprant generally well-tolerated with safety profile comparable to placebo Neumora expects to share additional updates on navacaprant development program at J.P. Morgan Healthcare Conference; podium presentation Tuesday, January 14 at 8:15am PT WATERTOWN, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeuti

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neumora Therape

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November: Guggenheim's Inaugural Healthcare Innovation Conference: Members of management will participate in a fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Members of management will participate in a fireside chat on Monday, November 18, 2024, at 10:20 a.m. ET in New York, NY. A live webcast of each event will

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2024 to report its third quarter 2024 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participant

WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will host a roundtable discussion on the neuropsychiatric treatment landscape and role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The discussion will feature leading experts in neuropsychiatry and will take place on Thursday, September 12 at 8:00 a.m. ET. "We look forward to an engaging discussion with our panel of distinguished medical experts and to providing an overview of the potential for navacapra

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer's disease agitation, providing opportunity for multiple value-creating catalysts over next 18 months Strong financial position with $371.6 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the second quarter e

NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response NMRA-511 was generally well-tolerated at all dose levels in Phase 1 single ascending dose / multiple ascending dose study, with no serious adverse events reported to date Alzheimer's disease agitation is associated with increased morbidity and mortality and creates significant burden for patients and caregivers WATERTOWN, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical an

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice president, head of research and development. Dr. Lenz is a member of Neumora's Executive Team reporting to Henry Gosebruch, chief executive officer. "I am delighted to welcome Rob to the Neumora team. His deep domain expertise in neuroscience combined with his vast experience executing successful clinical trials to develop first-in-class medicines will be invaluable as we advance our innovative pipeline including our recently initiat